Albucol Interreg, FHNW School of Life Sciences

Workers, athletes, children, pensioners – every segment of the European population is affected by musculoskeletal disorders such as bone fractures and cartilage damage. The development and marketing of more effective tissue engineering products would enable hospitals and their doctors practising regenerative medicine to provide better care for their patients affected by these problems.

Four renowned laboratories in the Upper Rhine region specialising in biomaterials and bioengineering have joined forces to develop an innovative therapeutic strategy. The aim is to produce new materials for tissue engineering to treat incurable bone or cartilage damage and where the damaged area must be replaced with new tissue.

The project team, coordinated by Philippe Lavalle and his cross-border partners, is developing an implantable biomaterial that offers optimal compatibility with the organism, with the aim of improving the condition of patients with tissue damage. The new biomaterial will be developed from two natural proteins known for their excellent biocompatibility. It will serve as implantable replacement tissue to enable the healing of injured areas.

First, the protein-based structures must be designed and manufactured, and their qualities (strength, hardness, elasticity, shape, etc.) must be ensured. The next step will be to select the best materials from a biological point of view, analysing in particular their biocompatibility and immunological effects. Finally, the technology transfer phase from the laboratory to the hospital bed will be initiated with the help of our industrial partners in the Upper Rhine region. This will enable this therapeutic innovation to enter clinical trials within three years of the project's completion.

Flyer (PDF)